Thermo Fisher Scientific surprised with strong business figures in the first quarter of 2025, which is likely to be of great interest to investors, including those in Germany. The US company achieved revenue of $10.36 billion, significantly exceeding analysts’ estimates of $10.23 billion. Earnings per share (EPS) under GAAP rose by 15 percent to $3.98. On a non-GAAP basis, earnings per share were $5.15, slightly exceeding analysts’ expectations as well (Forecast: $5.10).
Growth in Key Areas
Particularly noteworthy is the growth in the specialty diagnostics segment, with a revenue increase of 3.5 percent to $1.15 billion, as well as a stable result in the laboratory products segment, with revenue of around $5.64 billion—this segment accounts for more than half of total revenue. Additionally, Thermo Fisher announced the acquisition of the cleaning and filtration business of Solventum for about $4.1 billion. This acquisition could further strengthen the portfolio and promote future growth.
Importance for German Investors
For German investors, Thermo Fisher is particularly interesting due to its leading position in the field of science and technology. The strong quarterly figures signal a stable demand for scientific products and services as well as solid market positioning. Analysts see potential for further stock price increases with a target price of about $665 (+53% from the current price).
Overall, Thermo Fisher appears to be a robust company with positive prospects for investors due to strong operational results and strategic expansions of its business.